Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Total Addressable Market 8
1.3 Industry Trends 10
2 Report Outline 11
2.1 Report Scope 11
2.2 Report Summary 11
2.3 Research Methodology 12
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Market Definition - Infoholic Research 13
3.2 Segmented Addressable Market (SAM) 13
3.2.1 Trends of Human Insulin market 14
3.3 Related Markets 15
3.3.1 Oncology (Cancer) Drugs 15
3.3.2 Active pharmaceutical ingredients (APIs) 16
3.3.3 Over the counter drugs (OTC) 16
3.3.4 Diabetes Drugs 17
4 Market Outline 18
4.1 Pipeline products 18
4.2 Market Segmentation 18
4.3 Porter 5(Five) Forces 19
4.4 PEST Analysis 20
5 Market Characteristics 21
5.1 Market Dynamics 22
5.1.1 Drivers 22
5.1.1.1 Increasing Aging Population 22
5.1.1.2 Increasing People Suffering with Diabetes 24
5.1.2 Opportunities 24
5.1.2.1 Increase healthcare spending 24
5.1.2.2 Patent Expiry for Blockbuster Drugs 25
5.1.3 Restraints 25
5.1.3.1 Complex regulatory process 25
5.1.3.2 High cost of insulin 25
5.1.4 DRO - Impact Analysis 27
5.1.5 Key Stakeholders 28
6 Insulin Types: Market Size and Analysis 29
6.1 Overview 29
6.2 Lantus 29
6.3 Humulin 29
6.4 Levemir 30
6.5 Humalog 30
6.6 NovoLog/NovoRapid 30
6.7 Tresiba 31
6.8 Basaglar/ Abasaglar 31
6.9 Toujeo 31
6.10 Apidra 32
Company: Sanofi 32
7 Types: Market Size and Analysis 33
7.1 Overview 33
7.2 Modern Insulin 34
7.2.1 Rapid Acting Insulin Analogs 34
7.2.2 Premixed analogue insulins 34
7.2.3 Long-acting insulin 34
7.3 Traditional Human Insulin 35
7.3.1 Regular Human Insulin 35
7.3.2 NPH Human Insulin 36
7.3.3 Pre-Mixed Insulin 36
8 Regions: Market Size and Analysis 37
8.1 Overview 37
8.2 North America 39
8.2.1 Overview 39
8.2.2 United States 40
8.2.3 Canada 41
8.3 Europe 41
8.3.1 Overview 41
8.3.2 United Kingdom 42
8.3.3 Germany 42
8.4 APAC 43
8.4.1 Overview 43
8.4.2 India 43
8.4.3 China 44
8.4.4 Japan 44
8.5 Rest of the World 45
8.5.1 Overview 45
8.5.2 Middle East and Africa 46
8.5.3 Brazil 46
9 Competitive Landscape 47
10 Vendor Profiles 50
10.1 Novo Nordisk A/S 50
10.1.1 Overview 50
10.1.2 Geographic Revenue 52
10.1.3 Business Focus 52
10.1.4 SWOT Analysis 53
10.1.5 Business Strategy 53
10.2 Sanofi 54
10.2.1 Overview 54
10.2.2 Geographic Revenue 57
10.2.3 Business Focus 57
10.2.4 SWOT Analysis 58
10.2.5 Business Strategy 58
10.3 Eli Lilly & Company Ltd 59
10.3.1 Overview 59
10.3.2 Business Focus 62
10.3.3 SWOT Analysis 63
10.3.4 Business Strategies 63
10.4 Astra Zenca PLC. 64
10.4.1 Overview 64
10.4.2 Geographic Presence 68
10.4.3 Business Focus 68
10.4.4 SWOT Analysis 69
10.4.5 Business Strategy 69
11 Companies to Watch For 70
11.1 GlaxoSmithKline plc 70
11.1.1 Overview 70
11.2 Julphar Gulf Pharmaceutical Industries. 71
11.2.1 Overview 71
11.2.2 Highlights 72
11.3 Biocon Ltd 72
11.3.1 Overview 72
11.4 Wockhardt 74
11.4.1 Overview 74
11.4.2 Highlights 74
11.5 Oramed 74
11.5.1 Overview 74
11.5.2 Highlights 75
11.6 SemBioSys Genetics Inc. 75
11.6.1 Overview 75
Annexure 76
Abbreviations 76